Mepivacaïne Hcl B. Braun

Mepivacaine, the active ingredient in Mepivacaine HCl B. Braun, is a local anesthetic presented as a sterile solution for epidural, intramuscular and perineural use. It provides reversible nerve blockade for minor surgical procedures, epidural analgesia and peripheral nerve blocks.

GNH USA supplies Mepivacaine HCl B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory support across multiple regions.

Mepivacaine is used as a local anesthetic for procedures involving the peripheral nervous system and spinal analgesia. - Minor surgical procedures: provides local anesthesia to facilitate the procedure. - Epidural analgesia: produces segmental sensory block for pain relief during labor or surgery. - Peripheral nerve block: enables targeted nerve blockade for postoperative analgesia.

Adverse reactions to Mepivacaine may range from mild, transient events to rare but serious complications.

Common Side Effects: - Transient numbness at the injection site. - Mild dizziness or light‑headedness. - Temporary tachycardia.

Serious or Rare Side Effects: - Allergic reaction including anaphylaxis. - Cardiac arrhythmia. - Seizure activity.

When using Mepivacaine, clinicians should consider several safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular monitoring: observe heart rate and blood pressure during and after administration. - Liver function: use caution in patients with severe hepatic impairment. - Pregnancy considerations: avoid unless benefit outweighs risk, as safety data are limited. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Mepivacaine may interact with other medicines; awareness of potential interactions helps minimise risk.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Monoamine oxidase inhibitors: increase risk of hypertensive crisis. - Beta‑adrenergic blockers: can potentiate bradycardia.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., erythromycin): may raise plasma levels of mepivacaine. - Diuretics: may alter electrolyte balance affecting drug action. - Other local anesthetics: concurrent use may increase systemic toxicity.